بيكالوتاميد تيڤع ١٥٠ ملغ إسرائيل - العربية - Ministry of Health

بيكالوتاميد تيڤع ١٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

ريزدرونات تيڤع ٣٥ ملغ إسرائيل - العربية - Ministry of Health

ريزدرونات تيڤع ٣٥ ملغ

abic marketing ltd - risedronic acid as sodium 35 mg - tablets - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.

تيڤعكوتان إسرائيل - العربية - Ministry of Health

تيڤعكوتان

teva pharmaceutical indust.ltd - clotrimazole 1 %; dexamethasone acetate 0.044 % - cream - dexamethasone - tevacutan is indicated for the treatment of mycotic infections of the skin complicated by inflammation and/or secondary infection.

تستوڤيرون ديپو إسرائيل - العربية - Ministry of Health

تستوڤيرون ديپو

bayer israel ltd - testosterone enantate 250 mg/ml - oily solution for injection - testosterone - testosterone replacement therapy in male hypogonadism, in cases where testosterone deficiency has been confirmed on the basis of clinical and lboratory evidence.inducing puberty in boys with delayed puberty (pubertas tarda).

اموكسكلاڤ تيڤع ٨٧٥ ملغ إسرائيل - العربية - Ministry of Health

اموكسكلاڤ تيڤع ٨٧٥ ملغ

salomon,levin & elstein ltd - amoxicillin as trihydrate 875 mg; clavulanic acid as potassium salt 125 mg - film coated tablets - ampicillin, combinations - short-term treatment of bacterial infections at the following sites: upper/lower respiratory tract infections, genito-urinary tract infections, skin and soft tissue infections, bone and joint infections, dental infections and other infections.

اوفلوكساسين تيڤع ٢٠٠ ملغ إسرائيل - العربية - Ministry of Health

اوفلوكساسين تيڤع ٢٠٠ ملغ

abic ltd. - ofloxacin 200 mg - tablets - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as:- acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - chronic and recurrent infections of the ear, nose, and throat. ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - infections of soft tissues and skin. - infections of the bones and joints. - abdominal infections including infections in the pelvis minor and bacterial enteritis. - infections of the kidney, urinary tract, and genital organs, gonorrhoea.prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).

بيكالوتاميد تيڤع ٥٠ ملغ إسرائيل - العربية - Ministry of Health

بيكالوتاميد تيڤع ٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 50 mg - tablets - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

أبيترن ٥٠ إسرائيل - العربية - Ministry of Health

أبيترن ٥٠

abic ltd. - diclofenac sodium 50 mg - suppositories - diclofenac - rheumatoid arthritis, osteoarthritis, low back pain and other acute musculoskeletal .disorders such as periarthritis, tendinitis, tenosynovitis, bursitis, sprains, strains and dislocation, ankylosing spondylitis and acute gout.control of pain and inflammation in orthopedic, dental, and other monor surgery.

لوثيماكس إسرائيل - العربية - Ministry of Health

لوثيماكس

salomon,levin & elstein ltd - loteprednol etabonate 5 mg / 1 ml - ophthalmic suspension - loteprednol - lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . the incidence of patients with clinically significant increases in iop (> or = 10 mmhg) was 1 % with lotemax adn 6 % with prednisolone acetate 1 %. lotemax should not be used in patients who require a more potent corticosteroid for this indication. lotemax is also indicated for the treatment of po

تريتايس ٢٫٥ ملغ إسرائيل - العربية - Ministry of Health

تريتايس ٢٫٥ ملغ

sanofi - aventis israel ltd - ramipril 2.5 mg - tablets - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.